The Pharmacoeconomics of Biologic Therapy for IBD

Overview

Journal Nat Rev Gastroenterol Hepatol

Specialty Gastroenterology

Date 2010 Feb 6

PMID 20134492

Citations 15

Authors

Russell D Cohen

Affiliations

Soon will be listed here.

Abstract

The past decade has been marked by the introduction and expanding use of biologic therapies for the induction and maintenance of response in patients with IBD. Although widely heralded for their efficacy, these agents have also stirred controversy over the potential economic impact that they will have upon the world's health-care systems. Traditional cost analyses had shown that IBD medication costs contributed minimally towards the overall costs associated with the disease; however, these studies were all conducted before the introduction of biologic therapies. At that time, a small minority of patients accounted for a disproportionately large percentage of the overall costs, suggesting that cost-savings could be realized if interventions decreased the utilization of health-care resources and associated costs. More recent studies have been heterogeneous in their design and findings-some have suggested that cost-savings realized due to a decrease in the utilization of health-care services may offset the higher costs of biologic agents. Incorporation of data on indirect cost-savings and quality of life improvements into ongoing and future analyses is required to allow for more accurate analyses of overall costs and cost-savings.

Citing Articles

Inflammatory bowel disease, colitis, and cancer: unmasking the chronic inflammation link.

Shahgoli V, Noorolyai S, Ahmadpour Youshanlui M, Saeidi H, Nasiri H, Mansoori B Int J Colorectal Dis. 2024; 39(1):173.

PMID: 39465427 PMC: 11513726. DOI: 10.1007/s00384-024-04748-y.

Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial.

Chaparro M, Donday M, Barreiro-de Acosta M, Domenech E, Esteve M, Garcia-Sanchez V Therap Adv Gastroenterol. 2022; 12:1756284819874202.

PMID: 35154384 PMC: 8832302. DOI: 10.1177/1756284819874202.

Role of Digital Health and Artificial Intelligence in Inflammatory Bowel Disease: A Scoping Review.

Majidova K, Handfield J, Kafi K, Martin R, Kubinski R Genes (Basel). 2021; 12(10).

PMID: 34680860 PMC: 8535572. DOI: 10.3390/genes12101465.

TRIM34 attenuates colon inflammation and tumorigenesis by sustaining barrier integrity.

Lian Q, Yan S, Yin Q, Yan C, Zheng W, Gu W Cell Mol Immunol. 2020; 18(2):350-362.

PMID: 32094504 PMC: 8027410. DOI: 10.1038/s41423-020-0366-2.

Recent advances in the management of perianal fistulizing Crohn's disease: lessons for the clinic.

Lopez N, Ramamoorthy S, Sandborn W Expert Rev Gastroenterol Hepatol. 2019; 13(6):563-577.

PMID: 31023087 PMC: 6545251. DOI: 10.1080/17474124.2019.1608818.

References

Jewell D, Satsangi J, Lobo A, Probert C, Forbes A, Ghosh S . Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol. 2005; 17(10):1047-52. DOI: 10.1097/00042737-200510000-00007. View

Bassi A, Dodd S, Williamson P, Bodger K . Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004; 53(10):1471-8. PMC: 1774248. DOI: 10.1136/gut.2004.041616. View

Hay J, Hay A . Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol. 1992; 14(4):309-17. DOI: 10.1097/00004836-199206000-00009. View

Cohen R, Waters H, Tang B, Rahman M . Effects of fistula on healthcare costs and utilization for patients with Crohn's disease treated in a managed care environment. Inflamm Bowel Dis. 2008; 14(12):1707-14. DOI: 10.1002/ibd.20530. View

Jaisson-Hot I, Flourie B, Descos L, Colin C . Management for severe Crohn's disease: a lifetime cost-utility analysis. Int J Technol Assess Health Care. 2004; 20(3):274-9. DOI: 10.1017/s0266462304001084. View

Cohen R, Larson L, Roth J, Becker R, Mummert L . The cost of hospitalization in Crohn's disease. Am J Gastroenterol. 2000; 95(2):524-30. DOI: 10.1111/j.1572-0241.2000.01779.x. View

Munkholm P, Langholz E, Davidsen M, Binder V . Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut. 1994; 35(3):360-2. PMC: 1374590. DOI: 10.1136/gut.35.3.360. View

Rutgeerts P, Geboes K, VANTRAPPEN G, Beyls J, KERREMANS R, Hiele M . Predictability of the postoperative course of Crohn's disease. Gastroenterology. 1990; 99(4):956-63. DOI: 10.1016/0016-5085(90)90613-6. View

Caprilli R, Andreoli A, Capurso L, Corrao G, DAlbasio G, Gioieni A . Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther. 1994; 8(1):35-43. DOI: 10.1111/j.1365-2036.1994.tb00158.x. View

10.

Hanauer S, Korelitz B, Rutgeerts P, Peppercorn M, Thisted R, Cohen R . Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology. 2004; 127(3):723-9. DOI: 10.1053/j.gastro.2004.06.002. View

11.

Sonnenberg A . Geographic variation in the incidence of and mortality from inflammatory bowel disease. Dis Colon Rectum. 1986; 29(12):854-61. DOI: 10.1007/BF02555363. View

12.

Loftus Jr E . Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004; 126(6):1504-17. DOI: 10.1053/j.gastro.2004.01.063. View

13.

Nguyen G, Tuskey A, Dassopoulos T, Harris M, Brant S . Rising hospitalization rates for inflammatory bowel disease in the United States between 1998 and 2004. Inflamm Bowel Dis. 2007; 13(12):1529-35. DOI: 10.1002/ibd.20250. View

14.

Rutgeerts P, Van Assche G, Vermeire S, DHaens G, Baert F, Noman M . Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 2005; 128(4):856-61. DOI: 10.1053/j.gastro.2005.01.010. View

15.

Arseneau K, Cohn S, Cominelli F, Connors Jr A . Cost-utility of initial medical management for Crohn's disease perianal fistulae. Gastroenterology. 2001; 120(7):1640-56. DOI: 10.1053/gast.2001.24884. View

16.

Bernstein C, Nabalamba A . Hospitalization, surgery, and readmission rates of IBD in Canada: a population-based study. Am J Gastroenterol. 2006; 101(1):110-8. DOI: 10.1111/j.1572-0241.2006.00330.x. View

17.

Faubion Jr W, Loftus Jr E, Harmsen W, Zinsmeister A, Sandborn W . The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology. 2001; 121(2):255-60. DOI: 10.1053/gast.2001.26279. View

18.

Whelan G, Farmer R, Fazio V, Goormastic M . Recurrence after surgery in Crohn's disease. Relationship to location of disease (clinical pattern) and surgical indication. Gastroenterology. 1985; 88(6):1826-33. DOI: 10.1016/0016-5085(85)90007-1. View

19.

Ferguson A, Sedgwick D, Drummond J . Morbidity of juvenile onset inflammatory bowel disease: effects on education and employment in early adult life. Gut. 1994; 35(5):665-8. PMC: 1374753. DOI: 10.1136/gut.35.5.665. View

20.

Cohen R . Cost utility of initial medical management for Crohn's disease perianal fistula. Gastroenterology. 2002; 122(4):1187-8; author reply 1188-90. DOI: 10.1053/gast.2002.32782. View